To explore the therapeutic effect of iguratimod combined with Tripterygium wilfordii multiglucoside tablets in the treatment of rheumatoid arthritis (RA) and its influence on knee joint function.
A total of 130 RA patients admitted to Linquan County People's Hospital from January 2022 to December 2024 were selectively included in the study and randomly divided into the observation group and the control group, with 65 cases in each group. The control group was treated with iguratimod, while the observation group was treated with iguratimod combined with Tripterygium wilfordii multiglucoside tablets. The clinical efficacy, C reactive protein (CRP), and anticyclic citrullinated peptide antibody (ACPA), knee joint function score, effusion depth, synovial thickness and the occurrence of adverse reactions of the two groups were compared.
After treatment, the total effective rate of the observation group was higher than that of the control group (89.23% vs. 73.85%, P<0.05). The levels of serum CRP and ACPA in both groups were lower than those before treatment (P<0.05), and those in the observation group were lower than those in the control group (P<0.05). The hospital for special surgery scores of both groups were lower than those before treatment (P<0.05), and the scores of the observation group were lower than those of the control group (P<0.05). The Lysholm scores of both groups were increased compared with those before treatment (P<0.05), and the scores of the observation group were higher than those of the control group (P<0.05). The depth of effusion and the thickness of synovial membrane in both groups were lower than those before treatment (P<0.05), and the decrease in the observation group was greater (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, but the difference was not statistically significant (12.31% vs. 9.23%, P>0.05).
RA patients can benefit significantly from the treatment of iguratimod combined with Tripterygium wilfordii multiglucoside tablets. Among them, Tripterygium wilfordii multiglucoside tablets, as an adjuvant therapy, can effectively reduce CRP levels, inhibit ACPA activity, and improve knee joint function, without increasing the risk of adverse reactions, and has good safety.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |